The program is in its third year monitoring individuals with these mutations to try to detect disease early, understand their risk, and develop preventive treatments.
The study found immunomodulatory and angiogenesis gene expression signatures, mutational profiles, and HLA types could help predict how patients respond to therapy.
A new study found that FOXA1 missense mutations were enriched in metastatic breast tumors and were associated with lower response to aromatase inhibitors.
Researchers used the methylCIBERSORT algorithm to determine the makeup of the tumor immune microenvironment of about 6,000 pediatric central nervous system tumors.
GeneCentric's RNA-based molecular profiling platform will identify relevant non-muscle invasive bladder cancer subtypes and markers for potential therapeutic options.
